Ligand Pharmaceuticals Inc (LGND)
NASDAQ:LGND
Want to see LGND full AI Analyst Report?
LGND Stock Chart & Stats
$231.82
-$2.36(-2.14%)
At close: 4:00 PM EST
$231.82
-$2.36(-2.14%)
Day’s Range― - ―
52-Week Range$98.89 - $247.38
Previous CloseN/A
Volume21.09K
Average Volume (3M)221.86K
Market Cap
$4.17B
Enterprise Value$4.70B
Total Cash (Recent Filing)$779.40M
Total Debt (Recent Filing)$451.98M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Aug 11, 2026EPS Estimate
2.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.84
Shares Outstanding20,041,061
10 Day Avg. Volume219,360
30 Day Avg. Volume221,858
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)3.59
Price to Sales (P/S)13.64
P/FCF Ratio74.76
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue17.13
Enterprise Value/Gross Profit17.37
Enterprise Value/Ebitda18.51
Forecast
1Y Price Target
$279.71Price Target Upside20.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)9.04
Revenue Forecast (FY)$283.73M
Bulls Say, Bears Say
Bulls Say
Balance Sheet And DealmakingA substantial cash balance and deployable capital provide flexibility to pursue accretive partnerships or acquisitions that can expand the royalty portfolio and drive long‑term revenue.
Regulatory ApprovalFDA approval of FILSPARI for a second rare kidney disease expands the drug's indications and increases the U.S. patient opportunity, supporting a larger royalty base for Ligand.
Royalty Revenue ModelLigand's fixed royalty arrangement on partner products means higher FILSPARI uptake converts directly into predictable revenue growth without adding heavy commercial costs.
Bears Say
Contract Revenue TimingContract revenue depends on milestone and payment timing, making near-term top-line results unpredictable and complicating quarterly comparisons.
Product Sales VolatilityCaptisol sales are subject to timing of orders, causing quarter-to-quarter swings that can create volatile reported revenue despite underlying demand.
Revenue VisibilityHeavy variability in contract and product revenue reduces visibility for short-term guidance and places greater emphasis on steady royalty streams for valuation.
Ligand Pharma News
LGND FAQ
What was Ligand Pharmaceuticals Inc’s price range in the past 12 months?
Ligand Pharmaceuticals Inc lowest stock price was $98.89 and its highest was $247.38 in the past 12 months.
What is Ligand Pharmaceuticals Inc’s market cap?
Ligand Pharmaceuticals Inc’s market cap is $4.17B.
When is Ligand Pharmaceuticals Inc’s upcoming earnings report date?
Ligand Pharmaceuticals Inc’s upcoming earnings report date is Aug 11, 2026 which is in 82 days.
How were Ligand Pharmaceuticals Inc’s earnings last quarter?
Ligand Pharmaceuticals Inc released its earnings results on May 07, 2026. The company reported $1.63 earnings per share for the quarter, missing the consensus estimate of $1.816 by -$0.186.
Is Ligand Pharmaceuticals Inc overvalued?
According to Wall Street analysts Ligand Pharmaceuticals Inc’s price is currently Undervalued.
Does Ligand Pharmaceuticals Inc pay dividends?
Ligand Pharmaceuticals Inc pays a Notavailable dividend of $0.456 which represents an annual dividend yield of N/A. See more information on Ligand Pharmaceuticals Inc dividends here
What is Ligand Pharmaceuticals Inc’s EPS estimate?
Ligand Pharmaceuticals Inc’s EPS estimate is 2.01.
How many shares outstanding does Ligand Pharmaceuticals Inc have?
Ligand Pharmaceuticals Inc has 20,041,061 shares outstanding.
What happened to Ligand Pharmaceuticals Inc’s price movement after its last earnings report?
Ligand Pharmaceuticals Inc reported an EPS of $1.63 in its last earnings report, missing expectations of $1.816. Following the earnings report the stock price went down -9.555%.
Which hedge fund is a major shareholder of Ligand Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in LGND
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ligand Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$279.71 (20.66% Upside)
$279.71 (20.66% Upside)
Blogger Sentiment
Bullish
LGND Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 33.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.1%
Last 30 Days ▼ 7.5%
Last 30 Days ▼ 7.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
97.30%
12-Months-Change
Fundamentals
Return on Equity
16.19%
Trailing 12-Months
Asset Growth
69.21%
Trailing 12-Months
Company Description
Ligand Pharmaceuticals Inc
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
LGND Company Deck
LGND Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was broadly positive: the company reported strong underlying operating momentum (royalty revenue +56% YoY, total revenue +14% YoY, adjusted EPS +23% YoY), meaningful near-term and long-term growth catalysts (Filspari approval and Palvella Phase III success), a transformative announced acquisition (XOMA) expected to be immediately accretive and to materially scale the portfolio, and a strong liquidity position. Key risks discussed include GAAP volatility from equity fair-value movements, lumpy Captisol/contract revenue and timing dependence on partner execution, and remaining uncertainty until the XOMA transaction closes and its tax attributes are fully quantified. Overall, the positives — including multiple high-value clinical and commercial catalysts and a materially enlarged, diversified portfolio — outweigh the highlighted near-term financial and timing uncertainties.View all LGND earnings summariesLGND Stock 12 Month Forecast
Average Price Target
$279.71
▲(20.66% Upside)
Technical Analysis
Apellis Pharmaceuticals
―
Scholar Rock Holding
―
Crinetics Pharmaceuticals
―
Kymera Therapeutics
―
MoonLake Immunotherapeutics
―
Ownership Overview
2.65% Insiders
45.39% Mutual Funds
18.35% Other Institutional Investors
7.17% Public Companies and
Individual Investors